The KIF6 Genotype Test - Guiding Personalized Therapy
Research indicates that KIF6 genotyping predicts coronary heart disease (CHD) risk and event reduction during atorvastatin and pravastatin therapy*

The KIF6 genotype test can provide information in addition to traditional risk factors to help with the identification of patients at increased risk for CHD events and the personalization of their treatment.

What is the KIF6 Genotype Test?
Coronary Heart Disease (CHD) risk assessment based on traditional risk factors, while important, still fails to predict a large number of events. Because genetics influences predisposition to CHD, analyzing polymorphisms associated with risk may help improve risk assessment.

Recent research indicates that KIF6 can predict risk of CHD events and risk reduction during atorvastatin and pravastatin therapy*.

Who We Are

We understand that every patient is unique and customized therapy is often necessary.  To address this need, we offer sophisticated risk insights from Berkeley HeartLab test results to help clinicians reduce risk and prevent the progression of cardiovascular disease.

In The News
Apr 12, 2010
Celera Presents Data Describing the Biology of KIF6, a Genetic Marker for the Management of CHD

Mar 24, 2010
Celera Publishes Data Extending the Association Between the KIF6 Gene Variant and Differential Reduction of Coronary Events from Statin Therapy to the Elderly with Prior Vascular Disease

*The benefit of statin therapy for KIF6 carriers has only been studied with atorvastatin and pravastatin therapy.  Preliminary studies indicate that this benefit may not be generalizable to all statins.